Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Nanobiotix flags up cancer vaccine potential of nanoparticle treatment

Monday, November 14, 2016 6:09
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Nanobiotix’s (EPA:NANO) flagship tumour treatment may also have potential as a cancer vaccine, the company revealed at a leading immuno-therapy conference over the weekend.

In one of three experiments carried out in collaboration with Thomas Jefferson hospital in Chicago, results suggested NBTXR3 actively stimulates the host immune system to attack tumour cells.

Elsa Borghi, Nanobiotix’s chief medical officer, said the research suggests NBTXR3 may be able to transform a tumour into an in situ vaccine by provoking an immune response and thus encouraging the body to attack other similar tumour cells.

This would overcome one of the main barriers to the use of immuno-therapy as a cancer treatmen, she said, namely that most tumours do not provoke an immune response, which renders immunotherapy ineffective in many patients.

A cancer vaccine would be a hugely significant departure for NBTXR3, as its development so far has been into the potential as an adjunct to radiotherapy.

Here, NBTXR3 nanoparticles are directly injected into cancerous tumours where they absorb the ionizing radiation delivered by radiotherapy and magnify its effect locally.

This shrinks the tumour making it easier to remove during surgery.

Two additional experiments at Thomas Jefferson indicated radiotherapy with NBTXR3 elicited a marked enhancement of Immunogenic Cell Death (ICD) compared to radiotherapy alone.

A second experiment into abscopal effects, meanwhile, showed that the NBTXR3 /radiotherapy combination meant a statistically significant increase in overall survival.

Laurent Levy, Nanobiotix’s chief executive,  added: “These exciting data show that NBTXR3 could be a potential game changer in Immuno-oncology combination landscape.

“This raises the possibility of synergies between NBTXR3, radiotherapy and immunotherapies.

“On the top of existing core developments of our product as a single agent, this is opening new doors for industrial collaborations.”

Nanobiotix presented the data at the 31 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), in Maryland.

Story by ProactiveInvestors

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.